1887

Abstract

A procedure for the mobilization of (SFV)-derived replicons using virus-like particles (VLPs) has been recently proposed. VLPs were obtained from 293T cells co-expressing the vesicular stomatitis virus glycoprotein (VSV-G) and a modified SFV replicon. Advantages of SFV VLPs include improved safety with a lack of sequence homology between components and reducing the risk of recombination events that could lead to the formation of autonomous particles. Characterization of SFV VLPs reveals a discrepancy in their ability to infect cells reported to be permissive. Furthermore, it was noted that not all viral envelopes were able to promote VLP release equally from transfected cells. These observations encouraged the examination of the molecular mechanisms supporting the different steps of VLP assembly and transduction. The use of a VSV-G related pathway for VLP entry into target cells was demonstrated; it was also observed that an internal ribosome entry site may not be adapted to control transgene expression in all cells. Finally, the need for a membrane-binding domain to obtain a fully active SFV replication complex and VLP formation was documented.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81103-0
2005-11-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/11/3129.html?itemId=/content/journal/jgv/10.1099/vir.0.81103-0&mimeType=html&fmt=ahah

References

  1. Abe A., Miyanohara A., Friedmann T. 1998; Enhanced gene transfer with fusogenic liposomes containing vesicular stomatitis virus G glycoprotein. J Virol 72:6159–6163
    [Google Scholar]
  2. Ahola T., Kujala P., Tuittila M., Blom T., Laakkonen P., Hinkkanen A., Auvinen P. 2000; Effects of palmitoylation of replicase protein nsP1 on alphavirus infection. J Virol 74:6725–6733 [CrossRef]
    [Google Scholar]
  3. Berglund P., Smerdou C., Fleeton M. N., Tubulekas I., Liljestrom P. 1998; Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16:562–565 [CrossRef]
    [Google Scholar]
  4. Bhattacharya J., Peters P. J., Clapham P. R. 2004; Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles. J Virol 78:5500–5506 [CrossRef]
    [Google Scholar]
  5. Bijlmakers M. J., Marsh M. 2003; The on–off story of protein palmitoylation. Trends Cell Biol 13:32–42 [CrossRef]
    [Google Scholar]
  6. Choi K., Kim J. H., Li X., Paek K. Y., Ha S. H., Ryu S. H., Wimmer E., Jang S. K. 2004; Identification of cellular proteins enhancing activities of internal ribosomal entry sites by competition with oligodeoxynucleotides. Nucleic Acids Res 32:1308–1317 [CrossRef]
    [Google Scholar]
  7. Dorange F., Piver E., Bru T., Collin C., Roingeard P., Pages J. C. 2004; Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors. J Gene Med 6:1014–1022 [CrossRef]
    [Google Scholar]
  8. Ehrengruber M. U. 2002; Alphaviral gene transfer in neurobiology. Brain Res Bull 59:13–22 [CrossRef]
    [Google Scholar]
  9. Everts B., van der Poel H. G. 2005; Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12:141–161 [CrossRef]
    [Google Scholar]
  10. Fielding A. K. 2005; Measles as a potential oncolytic virus. Rev Med Virol 15:135–142 [CrossRef]
    [Google Scholar]
  11. Fischer R., Kohler K., Fotin-Mleczek M., Brock R. 2004; A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem 279:12625–12635 [CrossRef]
    [Google Scholar]
  12. Holm K., Weclewicz K., Hewson R., Suomalainen M. 2003; Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55(gag) associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J Virol 77:4805–4817 [CrossRef]
    [Google Scholar]
  13. Kaariainen L., Ahola T. 2002; Functions of alphavirus nonstructural proteins in RNA replication. Prog Nucleic Acid Res Mol Biol 71:187–222
    [Google Scholar]
  14. Kujala P., Ikaheimonen A., Ehsani N., Vihinen H., Auvinen P., Kaariainen L. 2001; Biogenesis of the Semliki Forest virus RNA replication complex. J Virol 75:3873–3884 [CrossRef]
    [Google Scholar]
  15. Laakkonen P., Ahola T., Kaariainen L. 1996; The effects of palmitoylation on membrane association of Semliki Forest virus RNA capping enzyme. J Biol Chem 271:28567–28571 [CrossRef]
    [Google Scholar]
  16. Larin S. S., Georgiev G. P., Kiselev S. L. 2004; Gene transfer approaches in cancer immunotherapy. Gene Ther 11:S18–S25 [CrossRef]
    [Google Scholar]
  17. Lebedeva I., Fujita K., Nihrane A., Silver J. 1997; Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes. J Virol 71:7061–7067
    [Google Scholar]
  18. Lefrancois L., Lyles D. S. 1982; The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes. Virology 121:168–174 [CrossRef]
    [Google Scholar]
  19. Leitner W. W., Ying H., Driver D. A., Dubensky T. W., Restifo N. P. 2000; Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51–55
    [Google Scholar]
  20. Leitner W. W., Hwang L. N., deVeer M. J., Zhou A., Silverman R. H., Williams B. R., Dubensky T. W., Ying H., Restifo N. P. 2003; Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9:33–39
    [Google Scholar]
  21. Li M., Yang C., Tong S., Weidmann A., Compans R. W. 2002; Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol 76:11845–11852 [CrossRef]
    [Google Scholar]
  22. Lundstrom K. 2001; Alphavirus vectors for gene therapy applications. Curr Gene Ther 1:19–29 [CrossRef]
    [Google Scholar]
  23. Lundstrom K. 2002; Alphavirus-based vaccines. Curr Opin Mol Ther 4:28–34
    [Google Scholar]
  24. Lundstrom K., Ziltener P., Hermann D., Schweitzer C., Richards J. G., Jenck F. 2001; Improved Semliki Forest virus vectors for receptor research and gene therapy. J Recept Signal Transduct Res 21:55–70 [CrossRef]
    [Google Scholar]
  25. Lundstrom K., Abenavoli A., Malgaroli A., Ehrengruber M. U. 2003; Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol Ther 7:202–209 [CrossRef]
    [Google Scholar]
  26. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. 2000; IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1:376–382 [CrossRef]
    [Google Scholar]
  27. Morita E., Sundquist W. I. 2004; Retrovirus budding. Annu Rev Cell Dev Biol 20:395–425 [CrossRef]
    [Google Scholar]
  28. Perri S., Driver D. A., Gardner J. P., Sherrill S., Belli B. A., Dubensky T. W. Jr, Polo J. M. 2000; Replicon vectors derived from Sindbis virus and Semliki Forest virus that establish persistent replication in host cells. J Virol 74:9802–9807 [CrossRef]
    [Google Scholar]
  29. Rheme C., Ehrengruber M. U., Grandgirard D. 2005; Alphaviral cytotoxicity and its implication in vector development. Exp Physiol 90:45–52 [CrossRef]
    [Google Scholar]
  30. Rolls M. M., Webster P., Balba N. H., Rose J. K. 1994; Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 79:497–506 [CrossRef]
    [Google Scholar]
  31. Rolls M. M., Haglund K., Rose J. K. 1996; Expression of additional genes in a vector derived from a minimal RNA virus. Virology 218:406–411 [CrossRef]
    [Google Scholar]
  32. Salonen A., Vasiljeva L., Merits A., Magden J., Jokitalo E., Kaariainen L. 2003; Properly folded nonstructural polyprotein directs the Semliki Forest virus replication complex to the endosomal compartment. J Virol 77:1691–1702 [CrossRef]
    [Google Scholar]
  33. Sandrin V., Russell S. J., Cosset F. L. 2003; Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 281:137–178
    [Google Scholar]
  34. Smerdou C., Liljestrom P. 1999; Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 73:1092–1098
    [Google Scholar]
  35. Smyth J. W., Fleeton M. N., Sheahan B. J., Atkins G. J. 2005; Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther 12:147–159 [CrossRef]
    [Google Scholar]
  36. Suomalainen M. 2002; Lipid rafts and assembly of enveloped viruses. Traffic 3:705–709 [CrossRef]
    [Google Scholar]
  37. Tseng J. C., Hurtado A., Yee H., Levin B., Boivin C., Benet M., Blank S. V., Pellicer A., Meruelo D. 2004a; Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 64:6684–6692 [CrossRef]
    [Google Scholar]
  38. Tseng J. C., Levin B., Hurtado A. 8 other authors 2004b; Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22:70–77 [CrossRef]
    [Google Scholar]
  39. Vasilakis N., Falvey D., Gangolli S. S., Coleman J., Kowalski J., Udem S. A., Zamb T. J., Kovacs G. R. 2003; Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors. Nat Biotechnol 21:932–935 [CrossRef]
    [Google Scholar]
  40. Whitt M. A., Rose J. K. 1991; Fatty acid acylation is not required for membrane fusion activity or glycoprotein assembly into VSV virions. Virology 185:875–878 [CrossRef]
    [Google Scholar]
  41. Willems W. R., Kaluza G., Boschek C. B., Bauer H., Hager H., Schutz H. J., Feistner H. 1979; Semliki Forest virus: cause of a fatal case of human encephalitis. Science 203:1127–1129 [CrossRef]
    [Google Scholar]
  42. Yao Y., Ghosh K., Epand R. F., Epand R. M., Ghosh H. P. 2003; Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant. Virology 310:319–332 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81103-0
Loading
/content/journal/jgv/10.1099/vir.0.81103-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error